Oncology Drugs
IASLC Highlights FDA Approval of VENTANA MET (SP44) RxDx Assay for NSCLC
Photo: Depositphotos

IASLC Highlights FDA Approval of VENTANA MET (SP44) RxDx Assay for NSCLC

International Association for the Study of Lung Cancer shared a post on LinkedIn:

“VENTANA MET (SP44) RxDx Assay receives FDA approval as a companion diagnostic for telisotuzumab vedotin-tllv in patients with high c-MET overexpression in NSCLC.

Read more in ILCN.”

Read OncoDaily’s Special Article on NSCLC․

NSCLC Lung cancer

c-MET cancer IASLC International Association for the Study of Lung Cancer Lung cancer NSCLC OncoDaily Oncology